Dupilumab Dosing for COPD
For adults with COPD, the recommended dose of Dupixent (dupilumab) is 300 mg subcutaneously every 2 weeks (Q2W), with no loading dose required. 1
Specific Dosing Details
The FDA-approved regimen for chronic obstructive pulmonary disease is straightforward:
- Dose: 300 mg subcutaneous injection
- Frequency: Every 2 weeks (Q2W)
- Loading dose: None required for COPD
- Administration: Can be self-administered after initial training
Patient Selection Criteria
Based on the most recent high-quality evidence, dupilumab should be considered for COPD patients with:
- Type 2 inflammation indicated by blood eosinophil counts ≥300 cells/µL 2, 3
- Persistent exacerbations despite triple therapy (inhaled corticosteroid + long-acting β2-agonist + long-acting muscarinic antagonist)
- Documented history of at least 2 moderate or 1 severe exacerbation in the previous year 2, 3
- Post-bronchodilator FEV1 typically 30-70% predicted 2
- Chronic productive cough for at least 3 months in the previous year 2
Clinical Efficacy
The pooled analysis of the BOREAS and NOTUS trials (1,874 patients) demonstrated that dupilumab 300 mg Q2W:
- Reduced annualized moderate or severe exacerbations by 31% (rate ratio 0.687; p<0.0001) 2
- Improved prebronchodilator FEV1 by 83 mL at week 12, sustained through week 52 3
- Improved quality of life (SGRQ score difference -3.4 points) 3
- Reduced respiratory symptom severity (E-RS-COPD score difference -1.1 points) 3
Real-world data shows rapid clinical response within 4 weeks, with improvements in symptoms (CAT score), lung function, and reduction in type 2 inflammatory biomarkers 4.
Administration Considerations
- Allow medication to reach room temperature for 45 minutes before injection 1
- Inject subcutaneously in abdomen, thigh, or upper arm
- First 1-2 injections should be administered in a clinical setting for training and monitoring
- After training, patients can self-administer at home
- If a dose is missed, administer within 7 days and resume original schedule; if >7 days, wait for next scheduled dose 1
Safety Profile
Treatment-emergent adverse events, serious adverse events, and discontinuation rates were similar between dupilumab and placebo groups in clinical trials 2, 3. The medication was well-tolerated in real-world settings with no treatment-related serious adverse events in short-term studies 4.
Important Distinction from Asthma Dosing
Note that COPD dosing differs from asthma: While asthma patients may receive either 200 mg Q2W or 300 mg Q2W (with loading doses of 400 mg or 600 mg respectively), COPD patients receive only the 300 mg Q2W regimen without a loading dose 1.